Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Eli Lilly announced that its oral GLP-1 drug, Foundayo (orforglipron), was associated with significant weight loss in women across all stages of menopause, including those with type 2 diabetes. Post-hoc analyses of over 1,500 participants in the ATTAIN-1 and ATTAIN-2 trials showed reductions in weight and waist circumference, addressing a major, often overlooked, driver of weight gain.
Why it matters
This development offers a new, convenient oral treatment option for weight management specifically tailored for menopausal women, a demographic often struggling with weight gain due to hormonal changes, potentially improving health outcomes and quality of life.
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)
The article is a press release from the drug manufacturer, presenting scientific findings. While promotional in nature, it reports on clinical trial data.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in